Citations

Clear

3138 citation(s) found for "Smith, AM".

Prognostic Factors in Limited-Stage Small Cell Lung Cancer
Farris, Michael K., Mix, M. , Wang, Xiaofei , Jaszewski, Brandy L., Foster, Nathan R. , Laurie, Fran, Smith, Koren, Alden, Ryan S. , Komaki, Ritsuko , Stinchcombe, Thomas E. , Bradley, Jeffrey D. , Bogart, Jeffrey A. , Jaszewski, Brandy, Bradley, Jeffrey , Farris, Michael K , Masters, Gregory A. , Razavian, Niema B , Vokes, Everett E.

Mayo Clinic

JAMA Network Open | October 24, 2024 | Volume: 7 | Issue: 10 | Pages: e2440673

10.1001/jamanetworkopen.2024.40673 | PMID 39446327 Get It

Importance The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Group B (CALGB) 30610–Radiation Therapy Oncology Group (RTOG) 0538 trial may impact future trial design. Objective To assess the comprehensive demographic, disease-related, treatment-related, and social factors for potential associations with survival outcomes and understand whether specific subpopulations may benefit from radiotherapy (RT) dose escalation in LS-SCLC. Design, Setting, and Participants This post hoc secondary analysis of a randomized clinical trial included 638 adults with LS-SCLC treated at 186 unique treatment sites with at least 1 accrual for all patients from March 15, 2008, to December 1, 2019; 313 patients were randomized to receive RT twice daily to a dosage of 45 Gy for 3 weeks and 325 to receive RT once daily to a dosage of 70 Gy for 7 weeks. Data were locked February 28, 2022, and analyzed from November 28, 2022, to June 4, 2024. Interventions Twice-daily RT or once-daily RT. Main Outcomes and Measures Multivariable Cox proportional hazards models evaluated the association of treatment groups and other risk factors with progression-free survival (PFS) and overall survival (OS). Patient-specific factors included age, sex, and Eastern Cooperative Oncology Group performance status. Disease-related factors included tumor, nodal, and overall cancer stages. Treatment-related factors included type of chemotherapy, timing of concurrent RT, RT technique, and prophylactic cranial irradiation. Social factors included marital status and treatment center accrual volume. Results Among 507 patients (260 [51.3%] female and 247 [48.7%] male; mean [SD] age, 62.6 [7.9] years) included in the multivariate survival analysis, with a median follow-up of 4.7 (IQR, 3.7-7.1) years, female sex was associated with improved OS (hazard ratio [HR], 0.73 [95% CI, 0.58-0.91]; P = .006), while being 70 years or older was associated with decreased OS (HR, 1.50 [95% CI, 1.14-1.98]; P = .004). Neither age nor sex was associated with PFS. When compared with those with N1 disease, OS and PFS were worse in patients with N2 (HRs, 1.64 [95% CI, 1.19-2.26]; P = .002 and 1.36 [95% CI, 1.02-1.81]; P = .04, respectively) and N3 (HRs, 2.03 [95% CI, 1.40-2.93]; P < .001 and 1.63 [95% CI, 1.17-2.26]; P = .004) disease. Compared with stage II cancer, OS was worse for stage IIIA (HR, 1.65 [95% CI, 1.17-2.31]; P = .004) and stage IIIB (HR, 1.94 [95% CI, 1.34-2.83]; P < .001). Compared with high-volume accrual centers, treatment at low- or middle-volume accrual centers was associated with worse PFS (HRs, 1.94 [95% CI, 1.33-2.82; P < .001] and 1.44 [95% CI, 1.15-1.82; P = .002], respectively) and worse OS (HRs, 1.55 [95% CI, 1.03-2.32; P = .03] and 1.33 [95% CI, 1.04-1.70; P = .02], respectively). Conclusions and Relevance This secondary analysis of the CALGB 30610–RTOG 0538 randomized clinical trial of patients with LS-SCLC found associations between female sex or being younger than 70 years and improved overall survival and between advanced nodal stage or treatment at low- or middle-volume accrual centers and worse outcomes. These findings suggest that stratification by nodal stage, clinical stage, and age should be considered in future randomized trials. Trial Registration ClinicalTrials.gov Identifier: NCT00632853
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits
Dragojevic, Sonja , Smith, Emily J. , Regan, Michael S. , Stopka, Sylwia A. , Baquer, Gerard , Xue, Zhiyi , Connors, Margaret A. , Kloeber, Jake A. , Hu, Zeng , Ott, Lauren L. , Carlson, Brett L. , Decker, Paul A. , Tian, Shulan , Laverty, Daniel J. , Eckel‐Passow, Jeanette E. , Elmquist, William F. , Agar, Nathalie Y.R. , Callaghan, Cameron M. , Zhang, Wenjuan , Connors, Margaret A , Kloeber, Jake A , Hu, Zeng , Bakken, Katrina K , Ott, Lauren L , Carlson, Brett L , Burgenske, Danielle M , Decker, Paul A. , Tian, Shulan , Gupta, Shiv K , Laverty, Daniel J , Eckel-Passow, Jeanette E , Elmquist, William F , Agar, Nathalie Y R , Nagel, Zachary D , Sarkaria, Jann N , Callaghan, Cameron M , Stopka, Sylwia A , Baquer, Gerard , Regan, Michael S , Zhang, Wenjuan , Bakken, Katrina K. , Burgenske, Danielle M. , Gupta, Shiv K. , Sarkaria, Jann N.

Mayo Clinic

Molecular Cancer Therapeutics | October 23, 2024 | Volume: 24 | Issue: 6 | Pages: 859-869

10.1158/1535-7163.mct-24-0003 | PMID 39440433 Get It

Abstract Glioblastoma (GBM) remains one of the most therapy-resistant malignancies with frequent local failures despite aggressive surgery, chemotherapy, and ionizing radiation (IR). Small molecule inhibitors of DNA-dependent protein kinase (DNA-PKi) are potent radiosensitizers currently in clinical trials. Determining which patients may benefit from radiosensitization with DNA-PKi is critical to avoid unnecessary increased risk of normal tissue toxicity. In this study, we used GBM patient-derived xenografts (PDX) in orthotopic murine models to study the relationship between molecular features, pharmacokinetics, and the radiosensitizing potential of the DNA-PKi peposertib. We show that peposertib radiosensitizes established and PDX GBM lines in vitro at 300 nmol/L and above, with a significant increase in radiosensitization by maintaining post-IR exposure for >12 hours. Radiosensitization by peposertib is mediated by catalytic inhibition of DNA-PK, and knockdown of DNA-PK by short hairpin RNA (shRNA) largely abolished the radiosensitizing effect. Peposertib decreased auto-phosphorylation of DNA-PKcs after IR in a dose-dependent manner with a delay in resolution of γH2AX foci at 24 hours. The addition of peposertib to IR significantly increased survival in GBM120 orthotopic xenografts, but not in GBM10. There was no difference in plasma or average tumor concentrations of peposertib in the two cohorts. Although the mechanism underpinning this discordant effect in vitro versus in vivo is not clear, there was an association for greater sensitization in TP53 mutant lines. Transfection of a dominant-negative TP53 mutant in baseline TP53 wild-type GBM lines significantly delayed growth and decreased nonhomologous end joining efficiency (but not homologous recombination), after peposertib exposure. See related commentary by Buchsbaum, p. 840
Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium
Satapathy, Sanjaya K. , Elwir, Saleh , Smith, Coleman I. , Jiang, Yu , Vanatta, Jason M. , Ha, Nghiem B. , Cheung, Amanda , Siddiqui, Mohammad Shadab , Rinella, Mary E. , Watt, Kymberly D., Sathapathy, Sanjaya , Rinella, Mary , Brandman, Danielle , Bhat, Mamatha , Patel, Pratik

Mayo Clinic

Transplantation | October 22, 2024 | Volume: 109 | Issue: 3 | Pages: 484-495

10.1097/tp.0000000000005236 | PMID 39434206 Get It

Background. Chronic kidney disease (CKD) is a well-recognized complication in patients undergoing liver transplantation (LT), particularly those with metabolic dysfunction-associated steatohepatitis (MASH), a leading cause of cirrhosis in the modern era. This study sought to refine risk stratification for CKD events post-LT in cirrhosis patients with MASH by leveraging baseline renal function at transplant. Methods. A total of 717 MASH cirrhosis patients who had LT (1997–2017) at 7 US centers (NailMASH Consortium) were analyzed. Patients were categorized by estimated glomerular filtration rate (eGFR) at transplant: low (LGFR, eGFR ≤30 mL/min/1.73 m²), medium (MGFR, eGFR >30–≤60 mL/min/1.73 m²), and high (HGFR, eGFR >60 mL/min/1.73 m²). Time-related eGFR intercepts, slopes, and assessments of advanced-stage CKD (aCKD) events, defined as 2 eGFR levels <30 mL/min/1.73 m² separated by ≥90 d, were examined. Results. Post-LT, LGFR group showed increased eGFR, whereas the HGFR group experienced a decline. The 3-mo mark was identified as a “reset point,” signifying a new reference level, beyond which a different rate of decline was observed. After 3 mo, mean eGFRs of the LGFR group approached MGFRs, whereas the mean eGFR of the HGFR group continued to decrease but remained higher than other groups during a 60-mo follow-up. LGFR patients had significantly higher aCKD probability than MGFR and HGFR groups. Subanalysis at 3 mo post-LT revealed more aCKD events in the LGFR group compared with MGFR and HGFR groups ( P < 0.0001). Conclusions. The study underscores renal impact of LT in MASH cirrhosis, indicating unique eGFR trajectories post-LT tied to baseline eGFR, with a reset point at 3 mo. Monitoring post-LT renal function, especially in those at aCKD risk, is crucial. Renal-sparing immunosuppression may help, regardless of baseline eGFR. Further studies are needed for interventions addressing renal dysfunction of patients with MASH post-LT.
Frequency and Genotype‐Dependence of intrinsic chronotropic insufficiency among patients with congenital long QT syndrome
Kulkarni, Veda, Pinsky, Alexa M. , Bos, J. Martijn , Bains, Sahej , Giudicessi, John R. , Allison, Thomas G. , Ackerman, Michael J. , Kulkarni, Veda K, Bains, Sahej , Giudicessi, J R , Ackerman, Michael J , Bos, Johan M , Neves, Raquel

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 21, 2024 | Volume: 36 | Issue: 1 | Pages: 17-23

10.1111/jce.16471 | PMID 39428612 Get It

AbstractIntroductionLong QT syndrome (LQTS) is a cardiac channelopathy characterized by QT prolongation and a potential for arrhythmic syncope, sudden cardiac arrest or deaths (SCA/SCD). It has been speculated that patients with LQTS might have a primary sinoatrial node (SAN) phenotype of chronotropic insufficiency (CI). This has not been demonstrated convincingly before because of the potentially confounding effects of beta blocker (BB) therapy. Herein, we set out to determine whether untreated patients with LQTS demonstrate intrinsic CI.Methods and ResultsA retrospective review of all treadmill exercise stress tests (TEST) was performed on patients with one of the three most common LQTS genotypes: LQT1, LQT2, and LQT3. For each patient, the first TEST completed while off BB was analyzed. Patients with prior left cardiac sympathetic denervation (LCSD) therapy were excluded. CI was defined as having an age‐ and gender‐predicted peak heart rate (HR) < 85% and/or a predicted HR reserve (HRR) < 80%. Overall, 463 LQTS patients (245 LQT1, 125 LQT2, and 93 LQT3) were included (267 female [58%]; mean age at time of TEST [29 ± 17 years]). Mean % predicted peak HR for all LQTS patients was 87.6% (range 42.9% ‐ 119.1%) and mean % predicted HRR was 80% (range 19.1% ‐ 153%). Overall, half of all LQTS patients (n = 234; 51%) displayed CI; 64% of patients with LQT1 (n = 157), 37% with LQT2 (n = 46), and 33% with LQT3 (n = 31). Patients with LQT1 were most likely to exhibit CI compared to patients with LQT2 (p < .0001) and LQT3 (p < .0001). CI was significantly more common in LQT1 compared to controls (p < .0001), while there was no difference between LQT2 (p = .5) or LQT3 and controls (p > .9). Presence of CI was not a predictor of LQTS‐associated symptoms, BB side effects or likelihood of future breakthrough cardiac events (BCE).ConclusionsPatients with LQTS, particularly LQT1, demonstrate a SAN phenotype of CI. If assessing BB therapy effect by impact on peak HR, the patient's pretreatment peak HR, rather than an age‐ and gender‐predicted maximum HR, should be used.
OS06.2.A RENEU: A PIVOTAL PHASE 2B TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA (PN)
Shuhaiber, Hans, Viskochil, David , Bielamowicz, Kevin , Lokku, A, Weintraub, Lauren , McNall‐Knapp, Rene , Hajjar, Fouad, Babovic‐Vuksanovic, Dusica , investigators, ReNeu, Moertel, Christopher L. , Hirbe, Angela C. , Sidhu, Alpa , Weber, Michael , Lokku, Armend, Smith, L, Foreman, Nicholas K. , Gershon, Timothy R. , investigators, ReNeu

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v20-v20

10.1093/neuonc/noae144.057 Get It

Abstract BACKGROUND PN in patients (pts) with NF1 can cause pain, disfigurement, impaired quality of life (QoL), and it can undergo malignant transformation. ReNeu (NCT03962543), a multicenter, open-label, phase 2b study, evaluated efficacy and safety of the highly selective, oral, investigational MEK1/2 inhibitor mirdametinib in adults (≥18 y) and children (2-17 y) with inoperable NF1 PN causing significant morbidities. MATERIAL AND METHODS Mirdametinib was administered as a capsule or dispersible tablet (2 mg/m2 BID, max 4 mg BID) without regard to food in 3 wk on/1 wk off 28-d cycles. The primary endpoint was confirmed objective response rate (ORR; percentage of pts with confirmed MRI-assessed ≥20% reduction of target PN volume by blinded independent central review [BICR] within the 24-cycle treatment phase). The minimum clinically relevant ORR (null) was defined as 23% for adults and 20% for children. Pts could continue treatment in an optional long-term follow-up (LTFU) phase. Additional key endpoints were duration of response (DoR), time to response (TTR), change from baseline in target PN volume, worst pain severity (Numerical Rating Scale-11 [NRS-11]), pain interference (Pain Interference Index [PII]), health-related (HR) QoL (PedsQL), and safety. RESULTS All 114 pts (58 adult, 56 children) received mirdametinib. As of the 20 Sept 2023 data cutoff (DCO), BICR-confirmed ORR during the treatment phase was 41% (95% CI, 29-55; P&lt;.001 vs null) in adults and 52% (95% CI, 38-65; P&lt;.001 vs null) in children. Two adults and 1 child had a confirmed response in the ongoing LTFU. Median (range) target PN volumetric best response from baseline was -41% (-90, 13) and -42% (-91, 48) in adult and children, respectively. As of the DCO, median treatment duration was 22 mo for each cohort, and median DoR was not reached. Median (range) TTR was 7.8 (4-19) mo in adults and 7.9 (4-19) mo in children. Adults and children had statistically significant improvements from baseline to Cycle 13 in NRS-11, PII, and key PedsQL measures. Most frequent (≥35% pts) treatment-emergent adverse events (TEAEs) were dermatitis acneiform, diarrhea, nausea, and vomiting in adults and diarrhea, dermatitis acneiform, and vomiting in children. 16% and 25% of adults and children, respectively, had grade ≥3 treatment-related AEs, and 22% and 9%, respectively, discontinued due to TEAEs. CONCLUSIONS In ReNeu, the largest multicenter NF1 PN trial reported to date, mirdametinib demonstrated a statistically significant ORR by BICR, with deep and durable PN volume reductions, significant improvements in pain severity, pain interference, and HRQoL, and a manageable safety profile in both adults and children. Together with a dispersible tablet formulation, these results underscore the potential of mirdametinib to become an important new treatment option for NF1 PN pts across all ages.
Evaluating adoption and reach in a pragmatic randomized trial of community paramedicine for intermediate acuity patient care
Ridgeway, Jennifer L. , Sundt, Wendy J., Krpata, Tami, Glasgow, Amy E. , Smith-Stellflug, Jamie L, Juntunen, Michael B. , Liedl, Chad P., Hentz, Joseph G. , McCoy, Jessica, Sundt, Wendy J S, Krpata, Tami S, Glasgow, Amy, Smith, Olivia A, Lampman, Michelle A. , Menser, Terri L, McCoy, Jessica J, Ridgeway, Jennifer L , Smith, Jamie L , Smith, Olivia A., Menser, Terri , McCoy, Rozalina G.

Mayo Clinic

Journal of Clinical and Translational Science | October 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.646 | PMID 39655042 Get It

Abstract Introduction: Pragmatic trials aim to speed translation to practice by integrating study procedures in routine care settings. This study evaluated implementation outcomes related to clinician and patient recruitment and participation in a trial of community paramedicine (CP) and presents successes and challenges of maintaining pragmatic study features. Methods: Adults in the pre-hospital setting, emergency department (ED), or hospital being considered for referral to the ED/hospital or continued hospitalization for intermediate-level care were randomized 1:1 to CP care or usual care. Referral and enrollment data were tracked administratively, and patient characteristics were abstracted from the electronic health record (EHR). Enrolled patients completed baseline surveys, and a subset of intervention patients were interviewed. All CPs and a sample of clinicians and administrators were invited to complete a survey and interview. Results: Between January 2022 and February 2023, 240 enrolled patients (42% rural) completed surveys, and 22 completed an interview; 63 staff completed surveys and 20 completed an interview. Ninety-three clinicians in 27 departments made at least one referral. Factors related to referrals included program awareness and understanding the CP practice scope. Most patients were enrolled in the hospital, but characteristics were similar to the primary care population and included older and medically complex patients. Challenges to achieving representativeness included limited EHR infrastructure, constraints related to patient consenting, and clinician concerns about patient randomization disrupting preferred care. Conclusion: Future pragmatic trials in busy clinical settings may benefit from regulatory policies and EHR capabilities that allow for real-world study conduct and representative participation. Trial registration: NCT05232799.
Arthroscopic Centralization of the Extruded Meniscus With Posterior Root Tear: A Technique Using Meniscotibial Ligament Fixation
Krych, Aaron J. , Meta, Fabien , Kang, Louis , Hevesi, Mario, Smith, Patrick A. , Krych, Aaron J , Kang, Louis S , Hevesi, Mario

Mayo Clinic

Arthroscopy Techniques | October 16, 2024 | Volume: 14 | Issue: 3 | Pages: No page available

10.1016/j.eats.2024.103274 | PMID 40207329 Get It

Abstract Meniscal root tears have been shown to significantly impact tibiofemoral mechanics and contribute to accelerated development of osteoarthritis. A common finding in conjunction with a meniscal root tear is extrusion of the meniscus. Meniscal extrusion is an independent risk factor for tibiofemoral cartilage loss and the progression of osteoarthritis. Meniscus centralization was first introduced to directly address extrusion alongside root repair techniques. To date, reported techniques for meniscus centralization generally involve anchoring the meniscus directly to the tibia in some fashion, which can limit the normal anatomic motion of the meniscus. We present a technique for meniscus centralization that aims to maintain natural meniscal motion by utilizing the meniscotibial ligaments. Technique Video video See video under supplementary data.
High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy
Han, Jianmin, Isom, Scott , Smith, Wesley, Begley, Stephanie, Jenneman, Dakota, Bose, Rupali, Seegars, Mary Beth, McCall, Chad M. , Hsi, Eric D. , Ghosh, Nilanjan

Mayo Clinic

Leukemia & Lymphoma | October 16, 2024 | Volume: 66 | Issue: 2 | Pages: 325-328

10.1080/10428194.2024.2414899 | PMID 39411845 Get It

Incidence, Mechanisms, and Clinical Characteristics of Traumatic Iritis: A Population-Based Analysis
Wang, Kenny Y. , Kim, B. Michelle, Xu, Timothy T. , Hodge, David O. , Smith, Wendy M. , Reynolds, Margaret

Mayo Clinic

Ocular Immunology and Inflammation | October 15, 2024 | Volume: 33 | Issue: 3 | Pages: 378-384

10.1080/09273948.2024.2413899 | PMID 39405056 Get It

Abstract We044: MATURITY OF HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES PROMOTED BY BRACHYURY PRIMING
Kargaran, Parisa K, Garmany, Ramin , Stutzman, Marissa Joy, Sadeghian, Maryam, Ackerman, Michael J. , Behfar, Atta, Terzic, Andre, Garmany, Armin , Sadeghian, Maryam , Behfar, Atta , Terzic, André , Garmany, Ramin

Mayo Clinic

Circulation Research | October 9, 2024 | Volume: 135 | Issue: Suppl_1 | Pages: AWe044-AWe044

10.1161/res.135.suppl_1.we044 Get It

Introduction: Cardiac differentiation protocols enable derivation of cardiomyocytes (CM). from human induced pluripotent stem cell (iPS). However, limited tools are available to ensure enhanced iPS-CM maturation without the need for prolonged and complex culture. Research Question: This study assessed whether the mesodermal and cardiopoiesis inductor, Brachyury (T), complements standard cardiac differentiation and augments structural and functional maturation of iPS-CM. Aims: The impact of T mRNA introduction prior to initiation of cardiac differentiation was characterized on: i) cardiac transcription factor expression; ii) structural and functional hallmarks of maturity; and iii) cardiotoxicity. Methods: RT-qPCR was employed to monitor the expression of cardiac-specific transcription factors. Transmission electron microscopy enabled the assessment of cellular ultrastructure. Seahorse measurements were used to determine basal respiration. Fluo4 staining was used to measure calcium transients with external field stimulation. Cardiotoxicity was measured as the impact of doxorubicin on calcium handling and cell survival. Results: Transfection with T prompted early and sustained upregulation of the cardiac transcription factors Nkx2.5 (10-fold; FDR<0.001) and MEF2C (7.2-fold; FDR<0.001). Mitochondrial area was increased with T transfection (P<0.001) and T-transfected iPS-CM exhibited greater basal respiration (FDR<0.05), greater calcium handling resilience in response to field stimulation, and a more mature transient morphology. Following doxorubicin exposure T transfected iPS-CM exhibited a greater compromise in calcium handling (FDR<0.001), and exaggerated cell death. Conclusion: Induction of human iPS with T prior to initiation of cardiac differentiation enhanced signatures of structural and functional maturity, and provided more robust readouts of drug toxicity.